Connect with our local chapter:
Today, Wednesday, December 19th, Roche/Genentech announced the US and Canadian locations for their upcoming study to test efficacy of the huntingtin-lowering therapy RG6042. This will be a 2-year study in people with early diagnosed HD. It will involve monthly lumbar punctures (spinal injections) to deliver RG6042 or a placebo, as well as clinical tests and scans to understand the effect of the drug on HD symptoms. Around 660 people age 25-65 will be recruited at approximately 90 sites across the world, including 20 sites in the US and 6 in Canada.


Click Here For Full Announcement From Roche/Genentech. ​